Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in Patients With Advanced Solid Tumors

NCT06998407 is registered in ClinicalTrials.gov with Avenzo Therapeutics, Inc. as lead sponsor.

NCT NCT06998407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06998407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-023 as a Single Agent, and in Combination With AVZO-021 and/or Endocrine Therapy in Patients With Advanced Solid Tumors
Lead sponsor
Avenzo Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 20, 2025
Completion date
August 31, 2030
Enrollment
380 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hr+, her2-, advanced breast cancer, hr+/her2- breast cancer